Regenerative medicine company Orthocell (ASX:OCC) has announced interim results from a new study evaluating the impact of sutures on nerve regeneration and functional recovery in the surgical repair of severed peripheral nerves.
Orthocell commissioned the Suturing Study to support the US Remplir sales rollout. It was conducted in collaboration with the company's Chief Scientific Officer and physician, Professor Minghao Zheng, as well as the University of Western Australia.
The company stated that interim results indicate that nerve repair with Remplir supports the earlier restoration of nerve function and superior regeneration of high-quality nerve tissue compared to standard-of-care suture-only repair.
Professor Zheng said, “Use of Remplir did not induce inflammation or scarring, resulting in better nerve regeneration. This outstanding local tissue response, combined with its optimal handling qualities, are key advantages of Remplir in nerve repair surgery. Use of Remplir will help surgeons to simplify the repair process, facilitate high quality nerve regeneration, and ultimately provide consistent and predictable outcomes to patients and support their return of function goals.”
Orthocell CEO and Managing Director, Paul Anderson, said, “We are delighted with the results from our Suturing Study, validating the superior Remplir clinical outcomes, previously published in a highly regarded, peer reviewed journal. These Study results provide key data to support the U.S. product sales roll out and rapid market adoption and will be a cornerstone of our US medical education efforts. We believe Remplir will redefine the nerve repair market and vastly improve the success of often complex nerve repair surgery.”